Cymru Marketing Journal - (CMJUK) - Online Business Journal & Digital Marketing Agency. Business News, Directory, SEO, Social Media Management, Advertising, Reviews, Forum, Market Research, Content Writing & Website Design. Thinking Local, Acting Global.

Category: CELL AND GENE THERAPY AI MARKETING ( www.CGTAI.com) (Page 2 of 2)

CGTAI (www.ctgai.com) Logo

Cell  Gene Therapy Ai (CGTAI) & Biotech Marketing 

The Domain www.cgtai.com is For Sale.

Please contact us to make an offer!

Welcome to CGTAI.com Biotech Marketing Business Journal.

All Press Releases and topics  of discussion are listed on our linked sites:

If you find our articles helpful, and well-written and would like us to write Biotech or AI content, just drop us a line. We will also give you backlinks and mention your articles on our site.

We also can provide banner advertising and perform SEO to get your articles on the first pages of search engines. We will market and advertise your business so that it can be seen by your targeted audience.

Gene Therapy Start-Ups Bluebird Bio

Gene Therapy Start-Ups Bluebird Bio

Country: USA | Funding: $484M
Bluebird Bio offers products based on the transformative potential of gene therapy for patients with genetic and orphan diseases.

bluebird bio | Pioneering Gene Therapies | Recode for Life

Who Are Bluebird Bio

Gene therapy is a revolutionary approach in the field of medicine that has the potential to cure genetic disorders by replacing, deleting, or repairing defective genes. One of the key players in the gene therapy industry is Bluebird Bio, a biotechnology company founded in 1992 that specializes in developing gene therapies for rare genetic diseases.

Bluebird Bio is a leading gene therapy company that has been at the forefront of developing transformative gene therapies for rare genetic diseases. The company’s focus on rare diseases is driven by the fact that many of these diseases have no existing treatments, leaving patients with few options for managing their conditions.

The company’s first gene therapy product, called Zynteglo, was approved by the European Medicines Agency (EMA) in 2019. Zynteglo is a treatment for beta-thalassemia, a rare blood disorder that results in the production of abnormal hemoglobin. The therapy involves inserting a functional copy of the beta-globin gene into the patient’s own stem cells, which are then transplanted back into the patient’s body. The therapy has been shown to eliminate the need for lifelong blood transfusions in some patients.

Bluebird Bio is also developing gene therapies for other rare diseases, including sickle cell disease, cerebral adrenoleukodystrophy (CALD), and multiple myeloma. The company’s sickle cell disease gene therapy, called LentiGlobin, is currently in clinical trials and has shown promising results in early studies. The therapy involves inserting a functional copy of the beta-globin gene into the patient’s own stem cells, which are then transplanted back into the patient’s body. The therapy has been shown to increase the production of healthy hemoglobin in patients, reducing the frequency of painful sickle cell crises.

In addition to its work on gene therapies, Bluebird Bio is also focused on developing innovative gene editing technologies. The company’s gene editing platform, called TALENs, uses custom-designed enzymes to precisely target and modify specific genes in the human genome. The technology has the potential to be used to treat a wide range of genetic diseases, including inherited disorders and certain types of cancer.

Bluebird Bio has been successful in securing significant funding to support its research and development efforts. The company has raised over $2 billion in funding from investors, including venture capital firms, strategic partners, and public markets. In 2018, the company entered into a strategic partnership with Regeneron Pharmaceuticals to develop gene therapies for genetic eye diseases.

While Bluebird Bio has made significant progress in the development of gene therapies, the field of gene therapy is still in its early stages, and there are many challenges that need to be overcome before these therapies can become widely available. These challenges include developing safe and effective delivery methods, optimizing dosing regimens, and addressing the high cost of gene therapies.

Bluebird Bio is a leader in the field of gene therapy, with a focus on developing transformative therapies for rare genetic diseases. The company’s successes in developing gene therapies for beta-thalassemia and sickle cell disease demonstrate the potential of gene therapy to provide life-changing treatments for patients with rare diseases. With its strong research and development capabilities, strategic partnerships, and significant funding, Bluebird Bio is well-positioned to continue making significant contributions to the field of gene therapy in the years to come.

How Does Bluebird Bio Market Their Business?

Bluebird Bio markets its business by primarily focusing on its innovative and transformative gene therapy products and technologies. The company employs various marketing strategies to raise awareness about its brand and products, build relationships with key stakeholders, and reach its target audience.

One of the key marketing strategies employed by Bluebird Bio is thought leadership. The company positions itself as a leader in the field of gene therapy by regularly publishing articles, presenting at scientific conferences, and participating in industry events. This approach helps to establish Bluebird Bio as a trusted and authoritative voice in the gene therapy space, which can help to attract investors, partners, and potential customers.

Bluebird Bio also uses content marketing to educate and engage its target audience. The company maintains an active blog and social media presence, where it shares updates on its research and development activities, highlights patient stories, and provides insights into the latest developments in the gene therapy field. By creating informative and engaging content, Bluebird Bio can attract and retain the attention of its target audience, which can help to build brand awareness and loyalty over time.

Another key marketing strategy employed by Bluebird Bio is strategic partnerships. The company has established partnerships with a variety of organizations, including academic institutions, pharmaceutical companies, and patient advocacy groups. These partnerships help to amplify Bluebird Bio’s message, expand its reach, and provide access to new resources and expertise. By working collaboratively with other organizations, Bluebird Bio can leverage the strengths of its partners to achieve its goals more efficiently and effectively.

Finally, Bluebird Bio uses traditional marketing channels such as advertising and public relations to promote its brand and products. The company may run targeted advertising campaigns in scientific journals or other industry publications to reach its target audience, or it may engage in media relations activities to secure coverage in mainstream media outlets. These activities help to increase the visibility of Bluebird Bio and its products, which can ultimately help to drive demand and support the company’s growth objectives.

In summary, Bluebird Bio markets its business by leveraging its innovative products and technologies, establishing thought leadership, engaging in content marketing, forming strategic partnerships, and using traditional marketing channels such as advertising and public relations. By using a variety of marketing strategies, Bluebird Bio can build brand awareness, attract customers and partners, and ultimately achieve its mission of developing life-changing gene therapies for patients with rare genetic diseases.

ADVERTISEMENT

If you found this article insightful and would like similar content written for your business, just drop us a line using the button below:

Cymru Marketing Banner AD
CGTAI (www.ctgai.com) Logo

#bluebirdbio #genetherapy #cellteraphy #cellandtherapyai #cgtai #biotechnology #biotechnologymarketing #biotechnologywriting #cgtaiwriting

Gene Therapy Start-Up Sangamo Bio-Sciences

Gene Therapy Start-Up Sangamo Bio-Sciences

Country: USA | Funding: $522.1M
Sangamo is a clinical-stage biopharmaceutical company focused on the research, development, and commercialization of engineered zinc finger DNA-binding proteins (ZFPs) as novel ZFP Therapeutics targeting various monogenic and infectious diseases with unmet medical needs.

Sangamo Therapeutics, Inc. | Pioneering Genetic Cures

Who Are Sangamo Bio-Sciences?

Sangamo Bio-Sciences is a leading biotechnology company specializing in gene therapy, gene editing, and cell therapy. The company is focused on developing innovative treatments for genetic diseases and disorders by utilizing its proprietary technologies, including zinc finger nucleases (ZFNs), TALE nucleases, and CRISPR/Cas9 gene editing systems.

Sangamo Bio-Sciences was founded in 1995 by Edward Lanphier, a biotechnology industry veteran. The company’s first breakthrough came in 1996 when it developed ZFN technology, a tool that can target specific genes in a patient’s DNA and modify them. This technology revolutionized the field of gene therapy and opened up new possibilities for treating genetic diseases.

Since then, the company has continued to advance its technology platform, expanding its focus to include cell therapy and gene editing. In 2015, Sangamo Bio-Sciences acquired TxCell, a French biotechnology company specializing in cell therapy, to broaden its expertise in the field. The acquisition enabled Sangamo Bio-Sciences to accelerate its efforts to develop CAR-T cell therapies, a promising new approach to cancer treatment.

Sangamo Bio-Sciences’ gene therapy approach involves introducing functional copies of a faulty gene into a patient’s cells to replace the defective ones. Gene editing, on the other hand, involves making precise changes to a patient’s DNA to correct or delete a faulty gene. The company’s cell therapy approach involves modifying a patient’s immune cells to target and destroy cancer cells.

One of Sangamo Bio-Sciences’ most promising therapies is SB-913, a gene therapy for Hunter syndrome, a rare genetic disorder that affects approximately 1 in 100,000 males. The therapy involves using a viral vector to introduce a functional copy of the gene that is missing or defective in patients with Hunter syndrome. The company has reported positive results from a Phase 1/2 clinical trial of SB-913, with patients showing sustained levels of the missing enzyme and a reduction in symptoms.

Sangamo Bio-Sciences has also made significant progress in developing gene editing therapies for a range of genetic diseases, including sickle cell disease, beta-thalassemia, and Huntington’s disease. The company’s proprietary In Vivo Protein Replacement Platform (IVPRP) enables the delivery of gene editing enzymes directly into a patient’s liver, allowing for precise editing of genes responsible for these diseases.

In addition to its proprietary technologies, Sangamo Bio-Sciences has also formed partnerships with other biotechnology companies and academic institutions to advance its research and development efforts. For example, the company has partnered with Pfizer to develop gene therapies for hemophilia, a genetic disorder that affects blood clotting.

Sangamo Bio-Sciences’ innovative approach to gene therapy, gene editing, and cell therapy has earned it a reputation as a leader in the field. The company has a strong pipeline of therapies in development and is well-positioned to bring innovative treatments to patients with genetic diseases and disorders. With continued investment in research and development, Sangamo Bio-Sciences is poised to make a significant impact on the field of gene therapy and revolutionize the treatment of genetic diseases.

How Does Sangamo Bio-Science Market Their Business?

Sangamo Bio-Sciences markets its business through a combination of traditional and modern marketing methods. Here are some ways the company promotes its products and services:

  1. Industry Conferences and Events: Sangamo Bio-Sciences attends and sponsors various conferences and events related to gene therapy, gene editing, and cell therapy. These events provide the company with the opportunity to showcase its technology and expertise, network with potential partners and customers, and stay up-to-date on the latest developments in the industry.
  2. Scientific Publications: Sangamo Bio-Sciences regularly publishes its research findings in scientific journals and presents at scientific conferences. This helps to establish the company as a thought leader in the field and promotes its technology to other researchers and potential partners.
  3. Digital Marketing: The company maintains an active website, social media profiles, and email newsletters to communicate with its customers, investors, and stakeholders. The website provides detailed information about the company’s technology, products, and services. Social media profiles are used to share news, research findings, and industry insights.
  4. Direct Sales and Partnerships: Sangamo Bio-Sciences has a dedicated sales team that markets its products and services directly to healthcare providers, researchers, and institutions. The company also partners with pharmaceutical companies, academic institutions, and government agencies to collaborate on research and development projects.
  5. Investor Relations: The company maintains an active investor relations program to communicate with its investors and potential investors. This includes regular earnings calls, presentations at investor conferences, and investor roadshows.

In summary, Sangamo Bio-Sciences markets its business through a variety of channels, including industry conferences, scientific publications, digital marketing, direct sales, partnerships, and investor relations. By leveraging these channels, the company is able to build its brand, showcase its technology, and attract new customers, partners, and investors.

ADVERTISEMENT

If you found this article insightful and need similar content for your site please contact us using the button below:

Cymru Marketing Banner AD

#SangamoBioSciences #genetherapy #cellteraphy #cellandtherapyai #cgtai #biotechnology #biotechnologymarketing #biotechnologywriting #cgtaiwriting

Gene Therapy Start-Up Tessera Therapeutics

Gene Therapy Start-Up Tessera Therapeutics

Country: USA | Funding: $531.8M
Tessera Therapeutics is pioneering Gene Writing – a new genome engineering technology that writes therapeutic messages into the genome to treat diseases at their source.

Tessera Therapeutics | A Flagship Pioneering Company

Who Are Tessera Therapeutics?

Gene therapy is a rapidly evolving field that aims to treat genetic disorders by introducing therapeutic genes into a patient’s cells. Tessera Therapeutics is a start-up that is at the forefront of this field, developing innovative gene editing and delivery technologies that have the potential to revolutionize the way we treat genetic diseases.

Founded in 2019, Tessera Therapeutics is a spin-out from the Broad Institute of MIT and Harvard, a world-renowned research institution that has made significant contributions to the field of genomics. The company is led by Chief Executive Officer Geoffrey von Maltzahn, a serial entrepreneur with a background in biotechnology and engineering.

Tessera’s approach to gene therapy is based on a novel technology called Gene Writing™, which is designed to precisely edit the genome to introduce therapeutic genes into specific cells or tissues. This technology involves the use of a programmable DNA-binding protein called a transcription activator-like effector (TALE), which can be customized to target specific sequences of DNA.

The Gene Writing™ technology is highly versatile, allowing Tessera to develop therapies for a wide range of genetic disorders, including those that are caused by single-gene mutations or more complex genetic changes. The company is currently focused on developing therapies for rare diseases, where there is a high unmet medical need and a limited number of treatment options.

Tessera’s Gene Writing™ technology is complemented by its proprietary platform for gene delivery, which is based on a class of viruses called adeno-associated viruses (AAVs). AAVs are naturally occurring viruses that are widely used in gene therapy because they are safe, non-pathogenic, and have the ability to infect a wide range of cell types.

Tessera has developed a suite of AAV vectors that are optimized for specific tissues or organs, allowing the company to target different parts of the body with precision. This platform has the potential to overcome some of the challenges associated with gene therapy, such as off-target effects, immune reactions, and limited tissue penetration.

One of the key advantages of Tessera’s approach is its ability to edit genes in vivo, meaning that the therapy can be delivered directly to the patient without the need for ex vivo manipulation of cells. This could greatly simplify the process of gene therapy and reduce the cost and complexity of treatment.

Tessera’s Gene Writing™ technology and AAV platform are still in the early stages of development, but the company has already made significant progress in bringing its therapies to the clinic. In December 2020, Tessera announced a collaboration with Biogen to develop gene therapies for neurological diseases, including amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

The collaboration with Biogen provides Tessera with significant financial resources and expertise in clinical development and regulatory affairs, which will be critical for advancing its therapies through clinical trials and toward commercialization. Tessera also recently announced a $230 million Series B funding round, which will support the company’s continued growth and expansion.

In summary, Tessera Therapeutics is a promising start-up that is using innovative gene editing and delivery technologies to develop therapies for genetic diseases. Its Gene Writing™ technology and AAV platform have the potential to overcome some of the limitations of existing gene therapies and provide a new approach to treating rare diseases. With the support of Biogen and other investors, Tessera is well-positioned to advance its therapies through clinical development and towards commercialization, bringing hope to patients with genetic disorders.

How does Tessera Therapeutics Market their Business?

As a biotech startup, Tessera Therapeutics primarily markets its business to investors, potential partners, and the scientific community. The company’s marketing efforts focus on highlighting its innovative gene editing and delivery technologies, as well as its strong scientific team and partnerships.

Tessera’s website serves as a primary marketing tool, providing information about the company’s technology platform, the pipeline of therapies, and scientific publications. The website also features news and press releases highlighting the company’s latest developments, collaborations, and funding rounds.

In addition to its website, Tessera uses social media platforms, such as Twitter and LinkedIn, to share news and updates with a wider audience. The company also attends scientific conferences and events to showcase its technology and network with potential partners and investors.

One of Tessera’s most significant marketing efforts to date has been its collaboration with Biogen, a leading biopharmaceutical company. The partnership not only provides Tessera with significant financial resources but also increases the company’s visibility within the industry and demonstrates the potential of its technology.

Overall, Tessera’s marketing strategy is focused on building awareness and credibility within the scientific community and attracting investors and partners who share the company’s vision of using gene editing and delivery technologies to transform the treatment of genetic diseases.

ADVERTISEMENT

If you found this article insightful and need similar content for your site please contact us using the button below:

Cymru Marketing Banner AD
CGTAI (www.ctgai.com) Logo

#TesseraTherapeutics #genetherapy #cellteraphy #cellandtherapyai #cgtai #biotechnology #biotechnologymarketing #biotechnologywriting #cgtaiwriting

Gene Therapy Start-Up Editas Medicine’s

Gene Therapy Start-Up Editas Medicine’s

Country: USA | Funding: $656.6M
Editas Medicine’s mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level.

Editas Medicine

Who Are Editas Medicines?

Editas Medicine is a biotechnology company that specializes in gene editing technology. The company was founded in 2013 by a group of leading scientists in the field of gene editing, including Feng Zhang, George Church, and Jennifer Doudna. Since its inception, Editas Medicine has been at the forefront of the gene therapy revolution, developing innovative therapies that have the potential to cure a wide range of diseases.

Gene editing technology allows scientists to modify an organism’s DNA in a precise and targeted way. This technology has enormous potential for treating genetic diseases, such as cystic fibrosis, sickle cell anemia, and Huntington’s disease. Editas Medicine has developed a range of gene editing tools, including the CRISPR/Cas9 system, which is widely considered to be one of the most powerful and precise gene editing tools available.

One of the most exciting applications of gene editing technology is in the field of medicine. Editas Medicine is working on a range of therapies that have the potential to cure or treat genetic diseases. One such therapy is for Leber congenital amaurosis (LCA), a rare genetic disorder that causes blindness. Editas Medicine has developed a gene therapy that uses the CRISPR/Cas9 system to correct the mutation that causes LCA. The therapy has shown promising results in preclinical studies, and the company plans to begin clinical trials in the near future.

Editas Medicine is also developing gene therapies for other genetic diseases, including sickle cell anemia, beta-thalassemia, and Duchenne muscular dystrophy. These therapies have the potential to transform the lives of millions of people around the world who suffer from these diseases.

In addition to its work in gene therapy, Editas Medicine is also developing a range of other gene editing technologies. These include tools for agricultural applications, such as creating crops that are more resistant to pests and diseases, and for industrial applications, such as creating bacteria that can produce valuable chemicals and fuels.

Editas Medicine has attracted significant investment from some of the world’s leading biotech investors, including Google Ventures, Polaris Partners, and Third Rock Ventures. The company has also formed partnerships with leading pharmaceutical companies, such as Allergan and Juno Therapeutics, to develop new gene therapies.

Despite its successes, Editas Medicine has faced some challenges in its journey to becoming a leading player in the gene therapy field. In 2018, the company was embroiled in a legal dispute with the Broad Institute of MIT and Harvard over the ownership of the CRISPR/Cas9 gene editing technology. The dispute was eventually resolved in Editas Medicine’s favor, but it highlights the complex legal and ethical issues surrounding gene editing technology.

Overall, Editas Medicine is a pioneering company that is at the forefront of the gene therapy revolution. Its cutting-edge gene editing technology has the potential to cure or treat a wide range of genetic diseases, and its innovative approach to gene editing has the potential to transform agriculture, industry, and many other fields. With significant investment and strong partnerships, Editas Medicine is well-positioned to continue its success and make a significant impact on the world.

How does Editas Medicines Market Their Business?

As a biotechnology company specializing in gene editing technology, Editas Medicine employs a range of marketing strategies to promote its business and attract investment, partners, and potential customers. Here are some ways Editas Medicine markets its business:

  1. Online Presence: Editas Medicine has a strong online presence, with an informative and engaging website that showcases its gene editing technology, team, and progress. The website features detailed descriptions of the company’s therapies and technology, as well as news and updates about its latest developments. The company also uses social media platforms like Twitter and LinkedIn to share news and connect with its audience.
  2. Conferences and Events: Editas Medicine frequently participates in scientific and industry conferences and events, where its team members give talks and presentations on the company’s technology and progress. These events provide opportunities for networking, building relationships with potential partners and investors, and gaining exposure to a wider audience.
  3. Partnerships and Collaborations: Editas Medicine has formed partnerships with leading pharmaceutical companies, including Allergan and Juno Therapeutics, to develop new gene therapies. These partnerships help to raise the profile of the company and demonstrate its expertise in the field of gene editing.
  4. Media Coverage: Editas Medicine has received extensive media coverage in the scientific, business, and mainstream press. The company’s groundbreaking research and potential to cure genetic diseases have captured the attention of journalists and investors alike. This media coverage helps to raise awareness of the company and its mission.
  5. Thought Leadership: Editas Medicine’s team members frequently publish papers in scientific journals and participate in panel discussions and interviews. By sharing their expertise and insights, the team members demonstrate the company’s leadership in the field of gene editing and position themselves as thought leaders.

In summary, Editas Medicine employs a range of marketing strategies, including online presence, conferences and events, partnerships, media coverage, and thought leadership, to promote its business and position itself as a leader in the field of gene editing technology.

ADVERTISEMENT

If you found this article insightful and need similar content for your site please contact us using the button below:

Cymru Marketing Banner AD
CGTAI (www.ctgai.com) Logo

#EditasMedicines #genetherapy #cellteraphy #cellandtherapyai #cgtai #biotechnology #biotechnologymarketing #biotechnologywriting #cgtaiwriting

Gene Therapy Start-Up Sana Biotechnology

Gene Therapy Start-Up Sana Biotechnology

Country: USA | Funding: $700M
Sana Biotechnology is a developer of engineered cells intended to be used as medicine for patients. It’s deploying a platform that can repair and control genes in cells or replace any cell in the body.

Home – Sana Biotechnology

Who Are Sana Biotechnology?

Gene therapy is a promising field that seeks to use genetic material to treat or cure various diseases. Sana Biotechnology is a biotech startup that was founded in 2018 to advance the development of gene therapies. The company is based in Seattle, Washington, and has raised over $700 million in funding to date.

Sana Biotechnology aims to develop genetic therapies that can target and treat a range of diseases, including cancer, neurological disorders, and rare genetic diseases. The company’s approach to gene therapy involves using modified viral vectors to deliver genetic material to specific cells in the body. This technology has the potential to provide long-lasting treatments that can correct genetic defects and restore normal cellular function.

One of Sana Biotechnology’s primary areas of focus is cancer. The company is developing gene therapies that can target cancer cells directly, without harming healthy cells. Sana’s approach involves using CAR-T cell therapy, which involves modifying the patient’s immune cells to recognize and attack cancer cells. The company is also developing therapies that can target specific mutations in cancer cells, which could lead to more personalized and effective treatments.

Sana Biotechnology is also developing gene therapies for neurological disorders, such as Alzheimer’s disease and Parkinson’s disease. The company’s approach involves using viral vectors to deliver genetic material to the brain, which can help to restore normal neuronal function. This technology has the potential to provide long-lasting treatments for these debilitating conditions.

In addition to cancer and neurological disorders, Sana Biotechnology is also working on gene therapies for rare genetic diseases. The company is using its expertise in viral vector technology to develop therapies that can correct genetic defects and restore normal cellular function. This could provide hope for patients who currently have few treatment options for their rare conditions.

Sana Biotechnology is still a relatively new company, but it has already made significant progress in the field of gene therapy. The company has assembled a team of experienced scientists and researchers who are dedicated to developing innovative therapies that can transform the lives of patients. With the backing of significant funding, Sana Biotechnology is well-positioned to continue advancing the development of gene therapies that can target a wide range of diseases.

Overall, Sana Biotechnology represents an exciting new player in the field of gene therapy. With its innovative technology and experienced team, the company has the potential to make significant contributions to the development of new treatments for cancer, neurological disorders, and rare genetic diseases. As research in this field continues to advance, Sana Biotechnology will be at the forefront of this exciting new frontier in medicine.

How does Sana Biotechnology Market Themselves?

As a relatively new biotech startup, Sana Biotechnology has been actively marketing itself in various ways to promote its mission and attract investors and partners. Here are a few ways that Sana Biotechnology has been marketing itself:

  1. Building a strong online presence: Sana Biotechnology has a website that provides detailed information about its technology, team, and research areas. The website also features news and press releases about the company, as well as job postings and events. The company has also created social media accounts on platforms like Twitter and LinkedIn, where they share updates and engage with their audience.
  2. Attending industry events: Sana Biotechnology has been attending various industry events and conferences to showcase its technology and connect with potential partners and investors. For example, the company participated in the JP Morgan Healthcare Conference in 2020, which is one of the largest healthcare conferences in the world.
  3. Partnering with other companies: Sana Biotechnology has formed partnerships with other companies in the biotech industry to further their research and development efforts. For example, in 2020, Sana Biotechnology announced a collaboration with Denali Therapeutics to develop gene therapies for neurological diseases.
  4. Issuing press releases: Sana Biotechnology regularly issues press releases to announce its latest developments and milestones. These press releases are distributed to various media outlets and can help raise awareness of the company’s technology and accomplishments.
  5. Hiring experienced professionals: Sana Biotechnology has been actively hiring experienced professionals in the biotech industry to join its team. By hiring top talent, the company is able to leverage the expertise of its employees to further its research and development efforts.

Overall, Sana Biotechnology has been marketing itself through a combination of online and offline efforts. By building a strong online presence, attending industry events, partnering with other companies, issuing press releases, and hiring experienced professionals, the company is positioning itself as a leading player in the field of gene therapy.

ADVERTISEMENT

If you found this article insightful and need similar content for your site please contact us using the button below:

Cymru Marketing Banner AD
CGTAI (www.ctgai.com) Logo

#SanaBiotechnology #genetherapy #cellteraphy #cellandtherapyai #cgtai #biotechnology #biotechnologymarketing #biotechnologywriting #cgtaiwriting

Gene Therapy Start-Up Autolus

Gene Therapy Start-Up Autolus

Country: UK | Funding: $781.6M
Autolus utilizes advanced cell programming CAR-T and manufacturing technologies and we have established a development-stage pipeline of products for the treatment of hematological malignancies and solid tumors.

Autolus – developing CAR T cell therapies for cancer patients

Who are Autolus and what do they do?

Autolus Bio-Technology is a biopharmaceutical company that specializes in the development of innovative gene therapies for the treatment of cancer. The company was founded in 2014 and is headquartered in London, United Kingdom.

The company’s primary focus is on the development of CAR-T cell therapies, which involve genetically modifying a patient’s own T cells to recognize and destroy cancer cells. Autolus Bio Technology’s proprietary technology platform allows for the creation of CAR-T cells with improved efficacy and safety profiles compared to traditional CAR-T therapies.

One of the company’s most advanced programs is AUTO1, a CD19-targeted CAR-T cell therapy for the treatment of B-cell malignancies. In clinical trials, AUTO1 has demonstrated high response rates and durable remissions in patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) and pediatric acute lymphoblastic leukemia (ALL).

Autolus Bio-Technology is also developing other CAR-T cell therapies, including AUTO2 for the treatment of multiple myeloma, AUTO3 for the treatment of DLBCL and pediatric ALL, and AUTO4 for the treatment of T cell lymphoma.

In addition to CAR-T cell therapies, Autolus Bio-Technology is also developing T cell receptor (TCR) therapies, which involve genetically modifying T cells to recognize cancer cells based on specific antigens. The company’s lead TCR therapy program is targeting solid tumors, including ovarian and lung cancers.

Autolus Bio-Technology has a strong pipeline of product candidates and a robust research and development program focused on the discovery of novel therapies for the treatment of cancer. The company has established partnerships with leading academic institutions and pharmaceutical companies to advance its research and development efforts.

Autolus Bio Technology’s mission is to develop innovative therapies that can transform the lives of patients with cancer. The company’s CAR-T cell and TCR therapies have the potential to revolutionize cancer treatment and offer new hope to patients who previously had limited treatment options.

Overall, Autolus Bio-Technology is a promising biopharmaceutical company with a strong focus on developing innovative gene therapies for the treatment of cancer. With a deep pipeline of product candidates and a commitment to advancing the field of gene therapy, Autolus Bio-Technology is well-positioned to make a significant impact in the fight against cancer.

How Does Autolus Market Their Business?

Autolus is a UK-based clinical-stage biopharmaceutical company that focuses on the development of next-generation, programmed T-cell therapies for the treatment of cancer. Their innovative approach to cancer treatment has garnered attention from investors and patients alike, and Autolus has become a leading player in the biotech industry. So how does Autolus market its business?

Autolus markets its business primarily through three channels: investor relations, media outreach, and patient advocacy.

Investor Relations:

As a publicly traded company, Autolus places a strong emphasis on investor relations. They regularly participate in investor conferences and events and maintain an active presence on social media platforms like Twitter and LinkedIn. Autolus also hosts quarterly earnings calls to update investors on their progress and financial performance. By maintaining a transparent and informative relationship with investors, Autolus is able to build trust and foster long-term relationships.

Media Outreach:

Autolus also places a strong emphasis on media outreach. They work with leading publications and journalists in the biotech industry to generate buzz and awareness around their innovative therapies. Autolus frequently publishes press releases and company updates to keep the media and the public informed about its progress. By maintaining an active and engaging presence in the media, Autolus is able to build a strong brand and establish itself as a thought leader in the industry.

Patient Advocacy:

Autolus recognizes that its work has the potential to make a profound impact on the lives of cancer patients. As such, they have placed a strong emphasis on patient advocacy. Autolus works with patient advocacy groups and non-profits to educate patients and their families about their therapies and the potential benefits they offer. By placing patients at the center of its mission, Autolus is able to build a strong community of supporters who are passionate about their work.

Conclusion

Autolus has built a strong marketing strategy that focuses on investor relations, media outreach, and patient advocacy. By establishing itself as a thought leader in the biotech industry and fostering strong relationships with investors and patients, Autolus has been able to generate buzz and excitement around its innovative therapies. As they continue to advance their pipeline and bring new therapies to market, Autolus will no doubt continue to be a major player in the biotech industry.

ADVERTISEMENT

If you found this article insightful and need similar content for your site please contact us using the button below:

Cymru Marketing Banner AD
CGTAI (www.ctgai.com) Logo

#autolus #genetherapy #cellteraphy #cellandtherapyai #cgtai #biotechnology #biotechnologymarketing #biotechnologywriting #cgtaiwriting

Gene Therapy Startup Intellia Therapeutics

Gene Therapy Startup Intellia Therapeutics

Country: USA | Funding: $1.2B (+)

Website: http://www.intelliatx.com

  • Genome modifying technologies
  • Recombination and DNAAcronym for deoxyribonucleic acid, the hereditary material in humans and almost all other organisms. DNA can be found in the cell nucleus and contains the genetic instructions for the development, functioning, growth, and reproduction of all known organisms. Nearly every cell in a person’s body has the same DNA. repairCorrection of “misspelled” disease-driving DNA sequence using a CRISPR/Cas9-based gene editing therapy. technologies
  • RNA therapeutic technologies
  • Therapeutic delivery of nucleic acids or ribonucleoproteins – viral and chemical
  • Engineered immune cell technologies
  • Novel target identification

Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for NTLA-2002, an In Vivo CRISPR-Based Investigational Therapy for the Treatment of Hereditary Angioedema (HAE) – Intellia Therapeutics (intelliatx.com)

Who are Intellia Therapeutics

Intellia Therapeutics is a biotechnology company founded in 2014 that focuses on developing gene editing therapies to treat genetic diseases. Based in Cambridge, Massachusetts, Intellia Therapeutics was founded by Jennifer Doudna, Emmanuelle Charpentier, and Rodger Novak, who were all pioneers in the development of the CRISPR/Cas9 gene-editing technology.

Intellia’s mission is to harness the power of CRISPR/Cas9 to develop curative treatments for genetic diseases. The company’s approach involves using CRISPR/Cas9 to edit the genetic code of patients with genetic diseases, correcting the underlying genetic mutations that cause the disease. Intellia believes that gene editing has the potential to provide a one-time, curative treatment for many genetic diseases, including inherited diseases such as sickle cell anemia, beta-thalassemia, and cystic fibrosis.

One of the key advantages of Intellia’s approach is its precision. By using CRISPR/Cas9, Intellia can target specific genes with incredible accuracy, minimizing the risk of off-target effects. This precision is essential for developing safe and effective gene editing therapies.

Intellia is also working to develop its gene editing platform for use in other applications, such as agricultural biotechnology and industrial biotechnology. The company has partnered with several leading companies in these fields to explore the potential of its gene editing technology.

Intellia’s lead program is focused on developing a curative treatment for transthyretin amyloidosis (ATTR), a rare genetic disease that causes the buildup of abnormal proteins in the body’s tissues and organs, leading to organ damage and failure. Intellia’s therapy involves using CRISPR/Cas9 to edit the DNA in liver cells, the source of the abnormal protein, to reduce or eliminate the production of the abnormal protein.

Intellia has also partnered with Regeneron Pharmaceuticals to develop gene editing therapies for a range of genetic diseases, including hemophilia and lysosomal storage disorders. The company has also partnered with Novartis to develop gene-editing therapies for cancer and autoimmune diseases.

Intellia’s innovative approach to gene editing has earned the company numerous awards and recognition, including being named a Technology Pioneer by the World Economic Forum and being named to the MIT Technology Review’s 50 Smartest Companies list. The company is well-funded, with backing from top venture capital firms and strategic partnerships with leading pharmaceutical and biotech companies.

Intellia Therapeutics is a leading biotechnology company focused on developing gene editing therapies for genetic diseases. Using the precision and power of CRISPR/Cas9, Intellia aims to provide one-time, curative treatments for a range of genetic diseases, offering new hope for patients and their families. With a strong pipeline of programs and strategic partnerships, Intellia is poised to make a significant impact in the field of gene editing and transform the lives of patients with genetic diseases.

How does Intellia market its business?

Intellia Therapeutics, as a biotechnology company, has a unique marketing approach that differs from traditional consumer-based marketing. Instead of marketing products directly to consumers, Intellia markets its business to investors, potential partners, and the scientific community.

One of the key ways Intellia markets its business is through scientific publications and presentations at industry conferences. By presenting its research and findings in prestigious scientific journals and conferences, Intellia can establish its expertise in the field of gene editing and gain credibility with potential investors and partners.

Intellia also uses social media and its website to share news and updates about its progress and achievements. They regularly post updates about their clinical trials, partnerships, and scientific breakthroughs. This helps to keep investors, partners, and the scientific community informed and engaged with the company’s progress.

In addition to these marketing efforts, Intellia has also participated in various media interviews, including television and print media, to increase awareness of the potential of gene editing and its unique approach to developing gene therapies.

Intellia also relies on its strategic partnerships with leading pharmaceutical and biotech companies to help promote its business. By partnering with established industry players, Intellia gains access to its network and resources, which can help to advance the development and commercialization of its gene editing therapies.

Conclusion

Intellia Therapeutics markets its business primarily through scientific publications, industry conferences, social media, and partnerships with leading pharmaceutical and biotech companies. By focusing on establishing credibility and awareness within the scientific and investment communities, Intellia is able to attract funding and partnerships that can help to advance the development of their innovative gene editing therapies.

ADVERTISEMENT

If you found this article insightful and wish us to write similar content or market your business just drop us a line.

Cymru Marketing Banner AD
CGTAI (www.ctgai.com) Logo

#biotech #nontechnology #partnerships #collaboration #CRISPR  #genomeediting #CRISPR/Cas9 #dna #genemodification #celltherapy #genetherapy #cellgenetherapyai #cgtai

Polyethylene glycol (PEG Allergy) as a cause of anaphylaxis

Polyethylene glycol (PEG Allergy) as a cause of anaphylaxis

Disclaimer:

This article is intended for people who have concerns about PEG Allergies and who need to safeguard their health and that of their families. It is NOT intended for those who are anti-vaccine and as such is NOT intended to adopt a discussion on the merits of vaccines on this blog. It is also NOT intended as an invitation for a discussion of the lethality of COVID-19 or the need for civic action to limit the spread of the disease.

Adverse Reactions.

I wrote my concerns about the adverse effects of having the Covid Vaccine in a previous article, I have since read further medical concerns which I will publish along with all the fact-checking citations.

People who have had a severe PEG Allergy in the past are advised to talk to a health professional before taking the vaccine.

The link to my previous article is below:

Polyethylene glycol (PEG) as a cause of anaphylaxis

Polyethylene glycols (PEGs) or macrogols are polyether compounds and are widely used as additives in pharmaceuticals, cosmetics, and food.

PEGs are also used in everyday products such as toothpaste and shampoo as thickeners, solvents, softeners, and moisture carriers, and they’ve been used as a laxative for decades. An increasing number of biopharmaceuticals include PEGylated compounds as well.

According to the MIT, PEGs are basically tiny, greasy spheres that are used in COVID vaccines to protect the active ingredient (mRNA) and help it penetrate cells. It is within cells that the mRNA can go to work priming the immune system.

PEGs have also been confirmed to cause allergic reactions in rare cases, but how rare is not known.

PEG-2000 is an ingredient used in both the Pfizer and Moderna COVID-19 vaccines. If the compound is found to be the cause of the six allergic reactions to date, it will help the CDC hone its guidance further by narrowing the list of those that should not receive the vaccine.

Instead, CDC guidelines recommend not giving the Pfizer or Moderna vaccines to anyone with a history of severe allergic reaction to any component of the vaccine. For people who have had a severe reaction to another vaccine or injectable medication, the risks and benefits of vaccination should be carefully weighed, CDC says.

Patients with undiagnosed PEG allergy often have a history of immediate onset-unexplained anaphylaxis or anaphylaxis to multiple classes of drugs or unexplained anaphylaxis. Such individuals should not be vaccinated with the Pfizer BioNTech vaccine, except on the expert advice of an allergy specialist. The AstraZeneca vaccine can be used as an alternative (unless otherwise contraindicated), particularly if they previously tolerated an injected influenza vaccine. The vaccine should be administered in a setting with full resuscitation facilities (e.g. a hospital), and a 30-minute observation period is recommended.

https://www.anaphylaxis.org.uk/covid-19-advice/pfizer-covid-19-vaccine-and-allergies/

Anaphylaxis

Anaphylaxis (pronounced ana-fil-ax-is) is a severe and often sudden allergic reaction. It can occur when someone with allergies is exposed to something, they are allergic (known as an allergen). Reactions usually begin within minutes and rapidly progress but can occur up to 2-3 hours later.

What are the causes of anaphylaxis?


The common causes of anaphylaxis include foods such as peanuts, tree nuts, milk, eggs, shellfish, fish, sesame seeds, and kiwi fruit, although many other foods have also been known to trigger anaphylaxis. Some people can react to tiny amounts of food, although this rarely causes a very severe reaction. Non-food causes include wasp or bee stings, natural latex (rubber), and certain drugs such as penicillin. In some people exercise can trigger a severe reaction – either on its own or in combination with other factors such as food or drugs (for example, aspirin).

Anaphylaxis-The-Facts-Feb-2019-1

https://www.anaphylaxis.org.uk/covid-19-advice/pfizer-covid-19-vaccine-and-allergies/

Polyethylene glycol side effects:

If experienced, these tend to have a Less Severe expression.

  • irritation of the rectum
  • a sleep disorder
  • excessive thirst
  • nausea
  • vomiting
  • stomach cramps
  • abdominal bloating
  • a feeling of general discomfort called malaise
  • intense abdominal pain
  • upper abdominal pain

INFREQUENT side effects

If experienced, these tend to have a Severe expression

  • low amount of magnesium in the blood
  • low amount of phosphate in the blood
  • low amount of calcium in the blood
  • a high amount of calcium in the blood
  • an increased sodium level in the blood
  • low amount of sodium in the blood
  • acidosis, a high level of acid in the blood
  • high levels of potassium in the blood
  • low amount of potassium in the blood
  • hives (My daughter had hives after her first vaccine and contrast dye)
  • a high amount of uric acid in the blood

If experienced, these tend to have a Less Severe expression

  • indigestion
  • headache
  • runny nose

RARE side effects

If experienced, these tend to have a Severe expression

  • high blood pressure
  • atrial fibrillation
  • abnormal heart rhythm
  • a feeling of throat tightness
  • rapid onset of fluid in the lungs
  • a puncture, tear, or hole in the esophagus
  • a type of stomach irritation called gastritis
  • insufficient blood supply to the colon
  • bleeding from the stomach, esophagus, or duodenum
  • decreased kidney function
  • fainting
  • seizures
  • muscle tremors
  • a skin rash
  • fluid retention in the legs, feet, arms, or hands
  • puffy face from water retention
  • swelling of the tongue
  • trouble breathing
  • a significant type of allergic reaction called anaphylaxis
  • a type of allergic reaction called angioedema
  • ulceration of the colon
  • lip swelling
  • fast heartbeat
  • asystole, stopping the heart

If experienced, these tend to have a Less Severe expression

  • skin inflammation
  • dizziness
  • heart throbbing or pounding

In the European anaphylaxis registry currently 7935 registered anaphylactic cases only three were induced by macrogol. These findings may imply that polyethylene glycol hypersensitivity is potentially life-threatening but probably underdiagnosed as many drugs and food items contain macrogol. Handling patients with macrogol hypersensitivity can be challenging because of the extensive allergology workup, the necessity of the physician’s expertise, and the limited avoidance options because many drugs, including those used for the treatment of allergic reactions such as antihistamines, may contain macrogol as an additive. Therefore, specific product labeling and awareness are required. Patients should be educated about drugs that may contain PEGs, but also other products like lubricants or ultrasound gels. An increased patient and physician awareness to the allergic potential of macrogol must be discussed before taking the Covid Vaccine.

The Centers for Disease Control (CDC) warns:

If you have had a severe allergic reaction—also known as anaphylaxis—to any ingredient in the Pfizer-BioNTech vaccine, you should not get vaccinated.*

*If you have had a severe allergic reaction to other vaccines or injectable therapies, ask your doctor if you should get the Pfizer-BioNTech vaccine. Your doctor will help you decide if it is safe for you to get the Pfizer-BioNTech vaccine.

PEG-2000 is an ingredient used in both the Pfizer and Moderna COVID-19 vaccines. If the compound is found to be the cause of the six allergic reactions to date, it will help the CDC hone its guidance further by narrowing the list of those that should not receive the vaccine. https://snacksafely.com/2020/12/what-we-know-about-peg-suspected-as-the-cause-of-reactions-to-pfizers-covid-19-vaccine/

https://www.webmd.com/drugs/2/drug-17118/polyethylene-glycol-3350-oral/details/list-sideeffects

https://aacijournal.biomedcentral.com/articles/10.1186/s13223-016-0172-7

https://www.sciencemag.org/news/2020/12/suspicions-grow-nanoparticles-pfizer-s-covid-19-vaccine-trigger-rare-allergic-reactions

FINAL THOUGHTS

If you have doubts speak to your local healthcare provider, or a health professional before taking the vaccine.

From personal experience, my daughter’s GP failed to mention that the reaction she had from an MRI contrast dye could well have been an anaphylaxis allergy, and was not advised about having her second vaccine. This is very worrying considering the same GP practice prescribed her Gaviscon which later transpired after we went to A&E that my daughter did not have gastric problems but was in fact diagnosed with Multiple Sclerosis.

#peg #pegallergy #Polyethyleneglycol #anaphylaxis #covidvaccine #covidvaccineanaphylaxis #covidvaccineallergicreaction

PFIZER-BIONTECH COVID-19 VACCINE – Adverse Reactions – Fact Checking.

Covid Vaccine Image

Reporting of Suspected Adverse Reactions Fact-Checking.

To report an adverse reaction to the vaccine please visit:

COVID-19 Vaccine Side Effects & Adverse Events (pfizersafetyreporting.com)

Also,

Official MHRA side effect and adverse incident reporting site for coronavirus treatments and vaccines | Coronavirus (COVID-19)

The side effects of the vaccine are as follows and can be read in the official PDF which you can download here:

Screenshot No 1.

Vaccine Screenshot 2
Temporary_Authorisation_HCP_Information_BNT162_6_0_UK_editclean

Fact – Checking

REUTERS

Who are Reuters: Reuters is an international news organization owned by Thomson Reuters. It employs some 2,500 journalists and 600 photojournalists in about 200 locations worldwide. Reuters is one of the largest news agencies in the world.

I found the above information on this website which is used by all media globally:

https://www.reuters.com/article/uk-factcheck-trial-idUSKBN28K1U3

https://www.reuters.com/article/uk-factcheck-vaccine/fact-check-document-does-not-show-the-covid-19-vaccine-will-be-used-for-depopulation-idUSKBN28F0I1

AstraZeneca published its peer-reviewed trial data in the British medical journal The Lancet on Dec. 8 for public scrutiny (reported by Reuters here).

Further Reading

https://www.who.int/news-room/q-a-detail/vaccines-and-immunization-what-is-vaccination?adgroupsurvey={adgroupsurvey}&gclid=Cj0KCQiA5bz-BRD-ARIsABjT4njG3fRywr2ITDzU9BzVcphyUczDeEmp6TUsSKzm9hUtxABCL_6IfTUaAheREALw_wcB

Yellow Card App

You can also download the Yellow Card App:

You can now receive news updates from the MHRA and report side effects to medicines via the Yellow Card app.

At the moment you will need to create a separate account on the app to report. Please download it from the Apple App Store, or Google Play Store.

If you have any comments on the app please contact us.

Caution

Vulnerable People Who Have Had: https://www.lemtrada.com/

Vulnerable People who have had Alemtuzumab should get additional medical advice before taking the PFIZER-BIONTECH COVID-19 VACCINE.

My daughter was treated with the drug Alemtuzuzumab.

Alemtuzumab WAS a medication used to treat chronic lymphocytic leukemia and multiple sclerosis. On July 3, 2020, Sanofi Genzyme was notified that our Lemtrada Home Phlebotomy Partner, Examination Management Services Inc., (EMSI) has gone out of business.

What Lemtrada warning said:

LEMTRADA can cause serious side effects including:

Serious autoimmune problems: Some people receiving LEMTRADA develop a condition where the immune cells in your body attack other cells or organs in the body (autoimmunity), which can be serious and may cause death. Serious autoimmune problems may include:

  • Immune thrombocytopenic purpura (ITP), is a condition of reduced platelet counts in your blood that can cause severe bleeding that may cause life‑threatening problems. Call your healthcare provider (HCP) right away if you have any of the following symptoms: easy bruising; bleeding from a cut that is hard to stop; coughing up blood; heavier menstrual periods than normal; bleeding from your gums or nose that is new or takes longer than usual to stop; small, scattered spots on your skin that are red, pink, or purple
  • Kidney problems called anti‑glomerular basement membrane disease, which, if not treated, can lead to severe kidney damage, kidney failure that needs dialysis, a kidney transplant, or death. Call your HCP right away if you have any of the following symptoms: swelling of your legs or feet; blood in the urine (red or tea‑colored urine); decrease in urine; fatigue; coughing up blood

It is important for patients to have blood and urine tests before they receive, while on treatment, and every month for 4 years or longer after they receive their last LEMTRADA infusion.

See the additional Screenshot of what the PDF says about adverse effects :

Screenshot No 2.

Vaccine Screenshot

***Thoughts From the Editor of this Post.

As with every drug we take there is an element of risk hence that is why we have leaflets inside the packaging about what the drug is and what side effects there are.

As a carer and a concerned mum, it is my duty to know if my daughter should have the vaccine, the following telephone numbers had auto-response messages saying the lines were busy before the calls were disconnected after my daughter tried phoning today.

029 218 36318

029 218 36319

029 218 36323

029 218 36340

We are located in Cardiff UK so hence these are Cardiff Numbers. If you are outside Wales you should look up your local health board in your region.

I advised my daughter to phone 111 and no one could advise her and she was told that someone would phone her back.

Upon further fact checking I personally phoned the secretary of the Professor of Neurology in Cardiff and I explained that my daughter was a patient and the secretary directed me to this site: https://cavuhb.nhs.wales/our-services/ms-multiple-sclerosis/ (The site does not explain anything about my concerns about diminished immune response) I also recited screenshot no 2 with my concerns and was told that all MS patients should have the vaccine although she could not explain what diminished immune response meant:

Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to the vaccine. No data are available about the concomitant use of immunosuppressants.
As with any vaccine, vaccination with COVID-19 mRNA Vaccine BNT162b2 may not protect all vaccine recipients.

So obviously not leaving any stone unturned and wanting to know what “diminished immune response” meant I found the following information:

Diminished Immune Response Meaning:

A diminished immune response underlies age-related SARS-CoV-2 pathologies – PubMed (nih.gov)

https://www.mayoclinic.org/diseases-conditions/primary-immunodeficiency/symptoms-causes/syc-20376905

Reading between the lines as I am no expert and I stand corrected if I am wrong, from what I understand my daughter should she decide on having the vaccine today will have her immune system diminished so there is no way for her to fight the virus. Furthermore and I quote: “No data is available about the concomitant use of immunosuppressants – may not protect all vaccine recipients“.

This tells me that it has no been tested on immune suppressant drugs or patients who have had immune suppressants, hence this is open for debate.

Other Links:

https://www.astrazeneca.com/our-company/contact-us.html

Contact:

To contact Astra Zeneca.

Prescription medicines

For medical enquiries about our products (including questions on how to take your medicine, to report a side effect, or make a complaint regarding one of our medicines), please call our UK-based Medical Information team on 0800 783 0033. Lines are open from Monday-Friday, 9 am-5 pm. Outside these hours and on bank holidays, an out-of-hours service is available to assist with any urgent enquiries.

Global Headquarters: +44 (0)20 3749 5000
UK Marketing Company (UKMC): 0800 783 0033

(If you are outside the UK please visit the link i have provided above).

To Contact PFIZER.

https://www.pfizer.co.uk/contact-us

Call 01304 616161
And ask to speak to the Medical Information team.

To Contact Gates Foundation – Vaccine.

https://www.gatesfoundation.org/Who-We-Are/General-Information/Contact-Us

https://www.gatesfoundation.org/what-we-do/global-health/vaccine-development-and-surveillance

The Oxford Vaccine.

https://www.ovg.ox.ac.uk/about/contact-us

https://www.research.ox.ac.uk/Area/coronavirus-research/vaccine

***If you have any concerns do contact the links I have provided or your Local Health Board.

#covid19 #covid #vaccine #oxfordvaccine #pfizer #pfizervaccine #astrazeneca #astrazenecavaccine #lemtrada #diminishedimmuneresponse #ms #multiplesclerosis #immunocompromised #itp #immunosuppressant

Newer posts »